BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Frejd FY, Kim KT. Affibody molecules as engineered protein drugs. Exp Mol Med 2017;49:e306. [PMID: 28336959 DOI: 10.1038/emm.2017.35] [Cited by in Crossref: 88] [Cited by in F6Publishing: 73] [Article Influence: 17.6] [Reference Citation Analysis]
Number Citing Articles
1 Miao H, Sun Y, Jin Y, Hu X, Song S, Zhang J. Application of a Novel 68Ga-HER2 Affibody PET/CT Imaging in Breast Cancer Patients. Front Oncol 2022;12:894767. [PMID: 35712499 DOI: 10.3389/fonc.2022.894767] [Reference Citation Analysis]
2 Chen Y, Sun W, Tang H, Li Y, Li C, Wang L, Chen J, Lin W, Li S, Fan Z, Cheng Y, Chen C. Interactions Between Immunomodulatory Biomaterials and Immune Microenvironment: Cues for Immunomodulation Strategies in Tissue Repair. Front Bioeng Biotechnol 2022;10:820940. [DOI: 10.3389/fbioe.2022.820940] [Reference Citation Analysis]
3 Zappala F, Higbee-Dempsey E, Jang B, Miller J, Yan L, Minutolo NG, Rosado González GT, Tsourkas A, Ozdemir BA. Rapid, site-specific labeling of "off-the-shelf" and native serum autoantibodies with T cell-redirecting domains. Sci Adv 2022;8:eabn4613. [PMID: 35522741 DOI: 10.1126/sciadv.abn4613] [Reference Citation Analysis]
4 Mcnulty MJ, Schwartz A, Delzio J, Karuppanan K, Jacobson A, Hart O, Dandekar A, Giritch A, Nandi S, Gleba Y, Mcdonald KA. Affinity Sedimentation and Magnetic Separation With Plant-Made Immunosorbent Nanoparticles for Therapeutic Protein Purification. Front Bioeng Biotechnol 2022;10:865481. [DOI: 10.3389/fbioe.2022.865481] [Reference Citation Analysis]
5 Li Z, Aboian MS, Zhu X, Marquez-Nostra B. Clinical Evaluation of Nuclear Imaging Agents in Breast Cancer. Cancers (Basel) 2022;14:2103. [PMID: 35565232 DOI: 10.3390/cancers14092103] [Reference Citation Analysis]
6 Gazvoda M, Dhanjee HH, Rodriguez J, Brown JS, Farquhar CE, Truex NL, Loas A, Buchwald SL, Pentelute BL. Palladium-Mediated Incorporation of Carboranes into Small Molecules, Peptides, and Proteins. J Am Chem Soc 2022. [PMID: 35438502 DOI: 10.1021/jacs.2c01932] [Reference Citation Analysis]
7 Gast V, Sandegren A, Dunås F, Ekblad S, Güler R, Thorén S, Tous Mohedano M, Molin M, Engqvist MKM, Siewers V. Engineering Saccharomyces cerevisiae for the production and secretion of Affibody molecules. Microb Cell Fact 2022;21:36. [PMID: 35264156 DOI: 10.1186/s12934-022-01761-0] [Reference Citation Analysis]
8 Parisi OI, Francomano F, Dattilo M, Patitucci F, Prete S, Amone F, Puoci F. The Evolution of Molecular Recognition: From Antibodies to Molecularly Imprinted Polymers (MIPs) as Artificial Counterpart. JFB 2022;13:12. [DOI: 10.3390/jfb13010012] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
9 Lwin TM, Turner MA, Amirfakhri S, Nishino H, Hoffman RM, Bouvet M. Fluorescence Molecular Targeting of Colon Cancer to Visualize the Invisible. Cells 2022;11:249. [DOI: 10.3390/cells11020249] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
10 Chong SE, Lee D, Oh JH, Kang S, Choi S, Nam SH, Yu J, Koo H, Lee Y. A dimeric α-helical cell penetrating peptide mounted with an HER2-selective affibody. Biomater Sci 2021;9:7826-31. [PMID: 34812802 DOI: 10.1039/d1bm00819f] [Reference Citation Analysis]
11 Akkapeddi P, Teng KW, Koide S. Monobodies as tool biologics for accelerating target validation and druggable site discovery. RSC Med Chem 2021;12:1839-53. [PMID: 34820623 DOI: 10.1039/d1md00188d] [Reference Citation Analysis]
12 Rudenko N, Fursova K, Shepelyakovskaya A, Karatovskaya A, Brovko F. Antibodies as Biosensors' Key Components: State-of-the-Art in Russia 2020-2021. Sensors (Basel) 2021;21:7614. [PMID: 34833687 DOI: 10.3390/s21227614] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Al-ani AW, Zamberlan F, Ferreira L, Bradshaw TD, Thomas NR, Turyanska L. Near-infrared PbS quantum dots functionalized with affibodies and ZnPP for targeted imaging and therapeutic applications. Nano Ex 2021;2:040005. [DOI: 10.1088/2632-959x/ac33b8] [Reference Citation Analysis]
14 Yamaguchi H, On J, Morita T, Suzuki T, Okada Y, Ono J, Evdokiou A. Combination of Near-Infrared Photoimmunotherapy Using Trastuzumab and Small Protein Mimetic for HER2-Positive Breast Cancer. Int J Mol Sci 2021;22:12213. [PMID: 34830099 DOI: 10.3390/ijms222212213] [Reference Citation Analysis]
15 Sayyadi N, Zhand S, Razavi Bazaz S, Warkiani ME. Affibody Functionalized Beads for the Highly Sensitive Detection of Cancer Cell-Derived Exosomes. Int J Mol Sci 2021;22:12014. [PMID: 34769444 DOI: 10.3390/ijms222112014] [Reference Citation Analysis]
16 Ramm I, Sanchez-Fernandez A, Choi J, Lang C, Fransson J, Schagerlöf H, Wahlgren M, Nilsson L. The Impact of Glycerol on an Affibody Conformation and Its Correlation to Chemical Degradation. Pharmaceutics 2021;13:1853. [PMID: 34834267 DOI: 10.3390/pharmaceutics13111853] [Reference Citation Analysis]
17 Lindberg J, Nilvebrant J, Nygren PÅ, Lehmann F. Progress and Future Directions with Peptide-Drug Conjugates for Targeted Cancer Therapy. Molecules 2021;26:6042. [PMID: 34641586 DOI: 10.3390/molecules26196042] [Reference Citation Analysis]
18 Persson J, Puuvuori E, Zhang B, Velikyan I, Åberg O, Müller M, Nygren PÅ, Ståhl S, Korsgren O, Eriksson O, Löfblom J. Discovery, optimization and biodistribution of an Affibody molecule for imaging of CD69. Sci Rep 2021;11:19151. [PMID: 34580321 DOI: 10.1038/s41598-021-97694-6] [Reference Citation Analysis]
19 Kamara S, Guo Y, Mao S, Ye X, Li Q, Zheng M, Zhu J, Zhang J, Du W, Chen J, Zhu S, Zhang L. Novel EBV LMP1 C-terminal domain binding affibody molecules as potential agents for in vivo molecular imaging diagnosis of nasopharyngeal carcinoma. Appl Microbiol Biotechnol 2021;105:7283-93. [PMID: 34505914 DOI: 10.1007/s00253-021-11559-6] [Reference Citation Analysis]
20 Mahmoudi R, Dianat-Moghadam H, Poorebrahim M, Siapoush S, Poortahmasebi V, Salahlou R, Rahmati M. Recombinant immunotoxins development for HER2-based targeted cancer therapies. Cancer Cell Int 2021;21:470. [PMID: 34488747 DOI: 10.1186/s12935-021-02182-6] [Reference Citation Analysis]
21 Ahirwar R. Recent advances in nanomaterials-based electrochemical immunosensors and aptasensors for HER2 assessment in breast cancer. Mikrochim Acta 2021;188:317. [PMID: 34476602 DOI: 10.1007/s00604-021-04963-2] [Reference Citation Analysis]
22 Molavipordanjani S, Hosseinimehr SJ. The Radiolabeled HER3 Targeting Molecules for Tumor Imaging. Iran J Pharm Res 2021;20:141-52. [PMID: 34400948 DOI: 10.22037/ijpr.2021.114677.14991] [Reference Citation Analysis]
23 Wan LQ, Zhang X, Zou Y, Shi R, Cao JG, Xu SY, Deng LF, Zhou L, Gong Y, Shu X, Lee GY, Ren H, Dai L, Qi S, Houk KN, Niu D. Nonenzymatic Stereoselective S-Glycosylation of Polypeptides and Proteins. J Am Chem Soc 2021;143:11919-26. [PMID: 34323481 DOI: 10.1021/jacs.1c05156] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
24 Santo AAE, Feliciano GT. Genetic Algorithms Applied to Thermodynamic Rational Design of Mimetic Antibodies Based on the GB1 Domain of Streptococcal Protein G: An Atomistic Simulation Study. J Phys Chem B 2021;125:7985-96. [PMID: 34264671 DOI: 10.1021/acs.jpcb.1c03324] [Reference Citation Analysis]
25 Shipunova VO, Sogomonyan AS, Zelepukin IV, Nikitin MP, Deyev SM. PLGA Nanoparticles Decorated with Anti-HER2 Affibody for Targeted Delivery and Photoinduced Cell Death. Molecules 2021;26:3955. [PMID: 34203547 DOI: 10.3390/molecules26133955] [Reference Citation Analysis]
26 Wang X, Luo D, Basilion JP. Photodynamic Therapy: Targeting Cancer Biomarkers for the Treatment of Cancers. Cancers (Basel) 2021;13:2992. [PMID: 34203805 DOI: 10.3390/cancers13122992] [Reference Citation Analysis]
27 Rawal S, Patel M. Bio-Nanocarriers for Lung Cancer Management: Befriending the Barriers. Nanomicro Lett 2021;13:142. [PMID: 34138386 DOI: 10.1007/s40820-021-00630-6] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
28 Li Y, Li W, Xu Z. Improvement on Permeability of Cyclic Peptide/Peptidomimetic: Backbone N-Methylation as A Useful Tool. Mar Drugs 2021;19:311. [PMID: 34072121 DOI: 10.3390/md19060311] [Reference Citation Analysis]
29 Elshiaty M, Schindler H, Christopoulos P. Principles and Current Clinical Landscape of Multispecific Antibodies against Cancer. Int J Mol Sci 2021;22:5632. [PMID: 34073188 DOI: 10.3390/ijms22115632] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
30 Sun R, Zhao Y, Wang Y, Zhang Q, Zhao P. An affibody-conjugated nanoprobe for IGF-1R targeted cancer fluorescent and photoacoustic dual-modality imaging. Nanotechnology 2021;32:205103. [PMID: 33556922 DOI: 10.1088/1361-6528/abe437] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
31 Zhong X, D'Antona AM. Recent Advances in the Molecular Design and Applications of Multispecific Biotherapeutics. Antibodies (Basel) 2021;10:13. [PMID: 33808165 DOI: 10.3390/antib10020013] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
32 Stiller C, Viktorsson K, Paz Gomero E, Hååg P, Arapi V, Kaminskyy VO, Kamali C, De Petris L, Ekman S, Lewensohn R, Karlström AE. Detection of Tumor-Associated Membrane Receptors on Extracellular Vesicles from Non-Small Cell Lung Cancer Patients via Immuno-PCR. Cancers (Basel) 2021;13:922. [PMID: 33671772 DOI: 10.3390/cancers13040922] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
33 Kaufman NEM, Dhingra S, Jois SD, Vicente MDGH. Molecular Targeting of Epidermal Growth Factor Receptor (EGFR) and Vascular Endothelial Growth Factor Receptor (VEGFR). Molecules 2021;26:1076. [PMID: 33670650 DOI: 10.3390/molecules26041076] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
34 Li Q, Li W, Xu K, Xing Y, Shi H, Jing Z, Li S, Hong Z. PEG Linker Improves Antitumor Efficacy and Safety of Affibody-Based Drug Conjugates. Int J Mol Sci 2021;22:1540. [PMID: 33546481 DOI: 10.3390/ijms22041540] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
35 Li M, Shi W, Yang J, Wang Q, Dong H, Chen J, Zhang L, Zhu S. Generation of a novel affibody molecule targeting Chlamydia trachomatis MOMP. Appl Microbiol Biotechnol 2021;105:1477-87. [PMID: 33521848 DOI: 10.1007/s00253-021-11128-x] [Reference Citation Analysis]
36 Guo R, Yang Y, Zhang D, Du J, Zhu X, Liu Y, Yang F, Lin J. A bispecific immunotoxin (IHPP) with a long half-life targeting HER2 and PDGFRβ exhibited improved efficacy against HER2-positive tumors in a mouse xenograft model. Int J Pharm 2021;592:120037. [PMID: 33161038 DOI: 10.1016/j.ijpharm.2020.120037] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
37 Voltà-Durán E, Serna N, Sánchez-García L, Aviñó A, Sánchez JM, López-Laguna H, Cano-Garrido O, Casanova I, Mangues R, Eritja R, Vázquez E, Villaverde A, Unzueta U. Design and engineering of tumor-targeted, dual-acting cytotoxic nanoparticles. Acta Biomater 2021;119:312-22. [PMID: 33189955 DOI: 10.1016/j.actbio.2020.11.018] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
38 Li S, Zou Y, Zhao D, Yin Y, Song J, He N, Liu H, Qian D, Li L, Huang H. Revisiting the phosphotyrosine binding pocket of Fyn SH2 domain led to the identification of novel SH2 superbinders. Protein Sci 2021;30:558-70. [PMID: 33314411 DOI: 10.1002/pro.4012] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
39 Islam T, Hasan MM, Awal A, Nurunnabi M, Ahammad AJS. Metal Nanoparticles for Electrochemical Sensing: Progress and Challenges in the Clinical Transition of Point-of-Care Testing. Molecules 2020;25:E5787. [PMID: 33302537 DOI: 10.3390/molecules25245787] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
40 Choi J, Wahlgren M, Ek V, Elofsson U, Fransson J, Nilsson L, Terry A, Söderberg CAG. Characterization of binding between model protein GA-Z and human serum albumin using asymmetrical flow field-flow fractionation and small angle X-ray scattering. PLoS One 2020;15:e0242605. [PMID: 33232370 DOI: 10.1371/journal.pone.0242605] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
41 Liu J, Cui D, Jiang Y, Li Y, Liu Z, Tao L, Zhao Q, Diao A. Selection and characterization of a novel affibody peptide and its application in a two-site ELISA for the detection of cancer biomarker alpha-fetoprotein. Int J Biol Macromol 2021;166:884-92. [PMID: 33157139 DOI: 10.1016/j.ijbiomac.2020.10.245] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
42 Chu W, Prodromou R, Day KN, Schneible JD, Bacon KB, Bowen JD, Kilgore RE, Catella CM, Moore BD, Mabe MD, Alashoor K, Xu Y, Xiao Y, Menegatti S. Peptides and pseudopeptide ligands: a powerful toolbox for the affinity purification of current and next-generation biotherapeutics. J Chromatogr A 2021;1635:461632. [PMID: 33333349 DOI: 10.1016/j.chroma.2020.461632] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
43 Abouzayed A, Tano H, Nagy Á, Rinne SS, Wadeea F, Kumar S, Westerlund K, Tolmachev V, Eriksson Karlström A, Orlova A. Preclinical Evaluation of the GRPR-Targeting Antagonist RM26 Conjugated to the Albumin-Binding Domain for GRPR-Targeting Therapy of Cancer. Pharmaceutics 2020;12:E977. [PMID: 33081166 DOI: 10.3390/pharmaceutics12100977] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
44 Moradipoodeh B, Jamalan M, Zeinali M, Fereidoonnezhad M, Mohammadzadeh G. Specific targeting of HER2-positive human breast carcinoma SK-BR-3 cells by amygdaline-ZHER2 affibody conjugate. Mol Biol Rep 2020;47:7139-51. [PMID: 32929653 DOI: 10.1007/s11033-020-05782-z] [Reference Citation Analysis]
45 Attwood MM, Jonsson J, Rask-Andersen M, Schiöth HB. Soluble ligands as drug targets. Nat Rev Drug Discov 2020;19:695-710. [PMID: 32873970 DOI: 10.1038/s41573-020-0078-4] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 6.5] [Reference Citation Analysis]
46 Zajc CU, Salzer B, Taft JM, Reddy ST, Lehner M, Traxlmayr MW. Driving CARs with alternative navigation tools - the potential of engineered binding scaffolds. FEBS J 2021;288:2103-18. [PMID: 32794303 DOI: 10.1111/febs.15523] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
47 Carrasco-López C, Zhao EM, Gil AA, Alam N, Toettcher JE, Avalos JL. Development of light-responsive protein binding in the monobody non-immunoglobulin scaffold. Nat Commun 2020;11:4045. [PMID: 32792484 DOI: 10.1038/s41467-020-17837-7] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
48 Garousi J, Orlova A, Frejd FY, Tolmachev V. Imaging using radiolabelled targeted proteins: radioimmunodetection and beyond. EJNMMI Radiopharm Chem 2020;5:16. [PMID: 32577943 DOI: 10.1186/s41181-020-00094-w] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
49 Garousi J, Vorobyeva A, Altai M. Influence of Several Compounds and Drugs on the Renal Uptake of Radiolabeled Affibody Molecules. Molecules 2020;25:E2673. [PMID: 32526905 DOI: 10.3390/molecules25112673] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
50 Barozzi A, Lavoie RA, Day KN, Prodromou R, Menegatti S. Affibody-Binding Ligands. Int J Mol Sci 2020;21:E3769. [PMID: 32471034 DOI: 10.3390/ijms21113769] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
51 Tans R, van Rijswijck DMH, Davidson A, Hannam R, Ricketts B, Tack CJ, Wessels HJCT, Gloerich J, van Gool AJ. Affimers as an alternative to antibodies for protein biomarker enrichment. Protein Expr Purif 2020;174:105677. [PMID: 32461183 DOI: 10.1016/j.pep.2020.105677] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
52 Zhao N, Ding B, Zhang Y, Klockow JL, Lau K, Chin FT, Cheng Z, Liu H. Reactive oxygen species and enzyme dual-responsive biocompatible drug delivery system for targeted tumor therapy. J Control Release 2020;324:330-40. [PMID: 32450093 DOI: 10.1016/j.jconrel.2020.05.031] [Cited by in Crossref: 7] [Cited by in F6Publishing: 1] [Article Influence: 3.5] [Reference Citation Analysis]
53 Saurabh S, Piazza F. Mesoscale computational protocols for the design of highly cooperative bivalent macromolecules. Sci Rep 2020;10:7992. [PMID: 32409687 DOI: 10.1038/s41598-020-64646-5] [Reference Citation Analysis]
54 Sadek J, Wuo MG, Rooklin D, Hauenstein A, Hong SH, Gautam A, Wu H, Zhang Y, Cesarman E, Arora PS. Modulation of virus-induced NF-κB signaling by NEMO coiled coil mimics. Nat Commun 2020;11:1786. [PMID: 32286300 DOI: 10.1038/s41467-020-15576-3] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 5.5] [Reference Citation Analysis]
55 Alhuseinalkhudhur A, Lubberink M, Lindman H, Tolmachev V, Frejd FY, Feldwisch J, Velikyan I, Sörensen J. Kinetic analysis of HER2-binding ABY-025 Affibody molecule using dynamic PET in patients with metastatic breast cancer. EJNMMI Res 2020;10:21. [PMID: 32201920 DOI: 10.1186/s13550-020-0603-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
56 Chandler PG, Buckle AM. Development and Differentiation in Monobodies Based on the Fibronectin Type 3 Domain. Cells 2020;9:E610. [PMID: 32143310 DOI: 10.3390/cells9030610] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 6.5] [Reference Citation Analysis]
57 Houshmand M, Garello F, Circosta P, Stefania R, Aime S, Saglio G, Giachino C. Nanocarriers as Magic Bullets in the Treatment of Leukemia. Nanomaterials (Basel) 2020;10:E276. [PMID: 32041219 DOI: 10.3390/nano10020276] [Cited by in Crossref: 15] [Cited by in F6Publishing: 7] [Article Influence: 7.5] [Reference Citation Analysis]
58 Crook ZR, Nairn NW, Olson JM. Miniproteins as a Powerful Modality in Drug Development. Trends Biochem Sci 2020;45:332-46. [PMID: 32014389 DOI: 10.1016/j.tibs.2019.12.008] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 5.5] [Reference Citation Analysis]
59 Biri-Kovács B, Adorján A, Szabó I, Szeder B, Bősze S, Mező G. Structure-Activity Relationship of HER2 Receptor Targeting Peptide and Its Derivatives in Targeted Tumor Therapy. Biomolecules 2020;10:E183. [PMID: 31991749 DOI: 10.3390/biom10020183] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
60 Bam R, Lown PS, Stern LA, Sharma K, Wilson KE, Bean GR, Lutz AM, Paulmurugan R, Hackel BJ, Dahl J, Abou-Elkacem L. Efficacy of Affibody-Based Ultrasound Molecular Imaging of Vascular B7-H3 for Breast Cancer Detection. Clin Cancer Res 2020;26:2140-50. [PMID: 31924738 DOI: 10.1158/1078-0432.CCR-19-1655] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
61 Zhu S, Chen J, Xiong Y, Kamara S, Gu M, Tang W, Chen S, Dong H, Xue X, Zheng ZM, Zhang L. Novel EBV LMP-2-affibody and affitoxin in molecular imaging and targeted therapy of nasopharyngeal carcinoma. PLoS Pathog 2020;16:e1008223. [PMID: 31905218 DOI: 10.1371/journal.ppat.1008223] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
62 Mazigi O, Schofield P, Langley DB, Christ D. Protein A superantigen: structure, engineering and molecular basis of antibody recognition. Protein Eng Des Sel 2019;32:359-66. [PMID: 31641749 DOI: 10.1093/protein/gzz026] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
63 Gebauer M, Skerra A. Engineering of binding functions into proteins. Current Opinion in Biotechnology 2019;60:230-41. [DOI: 10.1016/j.copbio.2019.05.007] [Cited by in Crossref: 14] [Cited by in F6Publishing: 6] [Article Influence: 4.7] [Reference Citation Analysis]
64 Yamaguchi H, Pantarat N, Suzuki T, Evdokiou A. Near-Infrared Photoimmunotherapy Using a Small Protein Mimetic for HER2-Overexpressing Breast Cancer. Int J Mol Sci 2019;20:E5835. [PMID: 31757056 DOI: 10.3390/ijms20235835] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
65 Bragina OD, Chernov VI, Zeltchan RV, Sinilkin IG, Medvedeva AA, Larkina MS. Alternative scaffolds in radionuclide diagnosis of malignancies. Bûll sib med 2019;18:125-33. [DOI: 10.20538/1682-0363-2019-3-125-133] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
66 Xu Y, Wang L, Pan D, Yu C, Mi B, Huang Q, Sheng J, Yan J, Wang X, Yang R, Yang M. PET imaging of a 68Ga labeled modified HER2 affibody in breast cancers: from xenografts to patients. Br J Radiol 2019;92:20190425. [PMID: 31593482 DOI: 10.1259/bjr.20190425] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
67 Omersa N, Podobnik M, Anderluh G. Inhibition of Pore-Forming Proteins. Toxins (Basel) 2019;11:E545. [PMID: 31546810 DOI: 10.3390/toxins11090545] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
68 Peltek OO, Muslimov AR, Zyuzin MV, Timin AS. Current outlook on radionuclide delivery systems: from design consideration to translation into clinics. J Nanobiotechnology 2019;17:90. [PMID: 31434562 DOI: 10.1186/s12951-019-0524-9] [Cited by in Crossref: 18] [Cited by in F6Publishing: 10] [Article Influence: 6.0] [Reference Citation Analysis]
69 Zorzi A, Linciano S, Angelini A. Non-covalent albumin-binding ligands for extending the circulating half-life of small biotherapeutics. Medchemcomm 2019;10:1068-81. [PMID: 31391879 DOI: 10.1039/c9md00018f] [Cited by in Crossref: 38] [Cited by in F6Publishing: 12] [Article Influence: 12.7] [Reference Citation Analysis]
70 Bam R, Laffey M, Nottberg K, Lown PS, Hackel BJ, Wilson KE. Affibody-Indocyanine Green Based Contrast Agent for Photoacoustic and Fluorescence Molecular Imaging of B7-H3 Expression in Breast Cancer. Bioconjug Chem 2019;30:1677-89. [PMID: 31082216 DOI: 10.1021/acs.bioconjchem.9b00239] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 5.3] [Reference Citation Analysis]
71 Cai H, Shi Q, Tang Y, Chen L, Chen Y, Tao Z, Yang H, Xie F, Wu X, Liu N, Yang Y, Wu H, Tian R, Lu X, Li L. Positron Emission Tomography Imaging of Platelet-Derived Growth Factor Receptor β in Colorectal Tumor Xenograft Using Zirconium-89 Labeled Dimeric Affibody Molecule. Mol Pharmaceutics 2019;16:1950-7. [DOI: 10.1021/acs.molpharmaceut.8b01317] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
72 Golinski AW, Holec PV, Mischler KM, Hackel BJ. Biophysical Characterization Platform Informs Protein Scaffold Evolvability. ACS Comb Sci 2019;21:323-35. [PMID: 30681831 DOI: 10.1021/acscombsci.8b00182] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 2.7] [Reference Citation Analysis]
73 Chen C, Wakabayashi T, Muraoka M, Shu F, Wei Shan C, Chor Kun C, Tim Jang C, Soehano I, Shimizu Y, Igawa T, Nezu JI. Controlled conductivity at low pH in Protein L chromatography enables separation of bispecific and other antibody formats by their binding valency. MAbs 2019;11:632-8. [PMID: 30898021 DOI: 10.1080/19420862.2019.1583996] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
74 Agnew HD, Coppock MB, Idso MN, Lai BT, Liang J, McCarthy-Torrens AM, Warren CM, Heath JR. Protein-Catalyzed Capture Agents. Chem Rev 2019;119:9950-70. [PMID: 30838853 DOI: 10.1021/acs.chemrev.8b00660] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 4.7] [Reference Citation Analysis]
75 Hober S, Lindbo S, Nilvebrant J. Bispecific applications of non-immunoglobulin scaffold binders. Methods 2019;154:143-52. [DOI: 10.1016/j.ymeth.2018.09.010] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
76 Tsuchimochi M, Yamaguchi H, Hayama K, Okada Y, Kawase T, Suzuki T, Tsubokawa N, Wada N, Ochiai A, Fujii S, Fujii H. Imaging of Metastatic Cancer Cells in Sentinel Lymph Nodes using Affibody Probes and Possibility of a Theranostic Approach. Int J Mol Sci 2019;20:E427. [PMID: 30669481 DOI: 10.3390/ijms20020427] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
77 Sutherland AR, Alam MK, Geyer CR. Post‐translational Assembly of Protein Parts into Complex Devices by Using SpyTag/SpyCatcher Protein Ligase. ChemBioChem 2018;20:319-28. [DOI: 10.1002/cbic.201800538] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
78 Richards DA. Exploring alternative antibody scaffolds: Antibody fragments and antibody mimics for targeted drug delivery. Drug Discovery Today: Technologies 2018;30:35-46. [DOI: 10.1016/j.ddtec.2018.10.005] [Cited by in Crossref: 31] [Cited by in F6Publishing: 25] [Article Influence: 7.8] [Reference Citation Analysis]
79 Fu R, Carroll L, Yahioglu G, Aboagye EO, Miller PW. Antibody Fragment and Affibody ImmunoPET Imaging Agents: Radiolabelling Strategies and Applications. ChemMedChem 2018;13:2466-78. [PMID: 30246488 DOI: 10.1002/cmdc.201800624] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 7.0] [Reference Citation Analysis]
80 Wuo MG, Hong SH, Singh A, Arora PS. Synthetic Control of Tertiary Helical Structures in Short Peptides. J Am Chem Soc 2018;140:16284-90. [PMID: 30395711 DOI: 10.1021/jacs.8b10082] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
81 Semeradtova A, Stofik M, Vankova L, Maly P, Stanek O, Maly J. Optical microchips based on high-affinity recombinant protein binders—Human serum albumin detection in urine. Sensors and Actuators B: Chemical 2018;272:441-7. [DOI: 10.1016/j.snb.2018.05.180] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
82 Altai M, Leitao CD, Rinne SS, Vorobyeva A, Atterby C, Ståhl S, Tolmachev V, Löfblom J, Orlova A. Influence of Molecular Design on the Targeting Properties of ABD-Fused Mono- and Bi-Valent Anti-HER3 Affibody Therapeutic Constructs. Cells 2018;7:E164. [PMID: 30314301 DOI: 10.3390/cells7100164] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
83 Bertok T, Lorencova L, Chocholova E, Jane E, Vikartovska A, Kasak P, Tkac J. Electrochemical Impedance Spectroscopy Based Biosensors: Mechanistic Principles, Analytical Examples and Challenges towards Commercialization for Assays of Protein Cancer Biomarkers. ChemElectroChem 2019;6:989-1003. [DOI: 10.1002/celc.201800848] [Cited by in Crossref: 55] [Cited by in F6Publishing: 17] [Article Influence: 13.8] [Reference Citation Analysis]
84 Samkoe KS, Bates BD, Elliott JT, LaRochelle E, Gunn JR, Marra K, Feldwisch J, Ramkumar DB, Bauer DF, Paulsen KD, Pogue BW, Henderson ER. Application of Fluorescence-Guided Surgery to Subsurface Cancers Requiring Wide Local Excision: Literature Review and Novel Developments Toward Indirect Visualization. Cancer Control 2018;25:1073274817752332. [PMID: 29334791 DOI: 10.1177/1073274817752332] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 4.8] [Reference Citation Analysis]
85 Zhu S, Zhu J, Song Y, Chen J, Wang L, Zhou M, Jiang P, Li W, Xue X, Zhao KN, Zhang L. Bispecific affibody molecule targeting HPV16 and HPV18E7 oncoproteins for enhanced molecular imaging of cervical cancer. Appl Microbiol Biotechnol 2018;102:7429-39. [PMID: 29938318 DOI: 10.1007/s00253-018-9167-2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
86 Baker AT, Aguirre-Hernández C, Halldén G, Parker AL. Designer Oncolytic Adenovirus: Coming of Age. Cancers (Basel) 2018;10:E201. [PMID: 29904022 DOI: 10.3390/cancers10060201] [Cited by in Crossref: 48] [Cited by in F6Publishing: 42] [Article Influence: 12.0] [Reference Citation Analysis]
87 Jiang P, Wang L, Hou B, Zhu J, Zhou M, Jiang J, Wang L, Chen S, Zhu S, Chen J, Zhang L. A novel HPV16 E7-affitoxin for targeted therapy of HPV16-induced human cervical cancer. Theranostics 2018;8:3544-58. [PMID: 30026865 DOI: 10.7150/thno.24607] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
88 Tsai WK, Wu AM. Aligning physics and physiology: Engineering antibodies for radionuclide delivery. J Labelled Comp Radiopharm 2018;61:693-714. [PMID: 29537104 DOI: 10.1002/jlcr.3622] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
89 Winkler J. Extrahepatic Targeting of Oligonucleotides with Receptor-Binding Non-Immunoglobulin Scaffold Proteins. Nucleic Acid Ther 2018;28:137-45. [PMID: 29733239 DOI: 10.1089/nat.2017.0713] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
90 Deonarain MP, Yahioglu G, Stamati I, Pomowski A, Clarke J, Edwards BM, Diez-Posada S, Stewart AC. Small-Format Drug Conjugates: A Viable Alternative to ADCs for Solid Tumours? Antibodies (Basel) 2018;7:E16. [PMID: 31544868 DOI: 10.3390/antib7020016] [Cited by in Crossref: 35] [Cited by in F6Publishing: 29] [Article Influence: 8.8] [Reference Citation Analysis]
91 Verdino P, Atwell S, Demarest SJ. Emerging trends in bispecific antibody and scaffold protein therapeutics. Current Opinion in Chemical Engineering 2018;19:107-23. [DOI: 10.1016/j.coche.2018.01.004] [Cited by in Crossref: 10] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
92 Rennig M, Martinez V, Mirzadeh K, Dunas F, Röjsäter B, Daley DO, Nørholm MHH. TARSyn: Tunable Antibiotic Resistance Devices Enabling Bacterial Synthetic Evolution and Protein Production. ACS Synth Biol 2018;7:432-42. [PMID: 29257878 DOI: 10.1021/acssynbio.7b00200] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
93 Harmansa S, Affolter M. Protein binders and their applications in developmental biology. Development 2018;145:dev148874. [PMID: 29374062 DOI: 10.1242/dev.148874] [Cited by in Crossref: 27] [Cited by in F6Publishing: 17] [Article Influence: 6.8] [Reference Citation Analysis]
94 Ham S, Min KA, Yang JW, Shin MC. Fusion of gelonin and anti-insulin-like growth factor-1 receptor (IGF-1R) affibody for enhanced brain cancer therapy. Arch Pharm Res 2017;40:1094-104. [PMID: 28900896 DOI: 10.1007/s12272-017-0953-7] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]